A 6-year-old boy with confirmed autism spectrum disorder (ASD) is referred to the child psychiatry clinic by his school. Teachers report that he has become increasingly aggressive toward peers during unstructured play, hits himself when frustrated, and has difficulty transitioning between activities. His parents confirm similar behaviors at home, with episodes lasting 10–15 minutes and occurring 3–4 times daily. He has no seizure history, normal hearing, and no known medical comorbidities. His IQ is estimated at 65 (moderate intellectual disability). Which of the following is the most appropriate first-line pharmacological intervention for his behavioral dyscontrol?

Explanation

## Pharmacological Management of Behavioral Dyscontrol in ASD ### Clinical Context This child presents with: - **Confirmed ASD diagnosis** with moderate intellectual disability (IQ 65) - **Aggression toward others** (hitting peers) - **Self-injurious behavior** (self-hitting) - **Severe behavioral dyscontrol** (3–4 episodes daily, 10–15 min duration) - **Difficulty with transitions** (a common trigger in ASD) - **No seizure history, normal hearing, no medical contraindications** ### Evidence-Based Pharmacotherapy for ASD Behavioral Symptoms ```mermaid flowchart TD A[ASD with behavioral dyscontrol<br/>aggression, self-injury]:::outcome --> B[Behavioral interventions first<br/>ABA, structured transitions,<br/>sensory regulation]:::action B --> C{Adequate response<br/>in 4-6 weeks?}:::decision C -->|Yes| D[Continue behavioral therapy]:::action C -->|No| E[Consider pharmacotherapy]:::action E --> F{Target symptom?}:::decision F -->|Aggression/<br/>self-injury| G[Risperidone or Aripiprazole]:::action F -->|Anxiety-driven<br/>behaviors| H[SSRI<br/>e.g., sertraline]:::action F -->|Hyperactivity/<br/>impulsivity| I[Stimulant<br/>if no tics]:::action G --> J[Baseline: metabolic panel,<br/>prolactin, weight, BP]:::action J --> K[Monitor: weight, metabolic<br/>parameters, EPS q3-6 months]:::action ``` ### Key Point: Antipsychotics for Aggression and Self-Injury in ASD **Risperidone and aripiprazole are the only FDA-approved medications for irritability in autism.** Risperidone is indicated specifically for aggression, self-injurious behavior, and severe tantrums in children with ASD aged 5–16 years. ### High-Yield: Dosing and Monitoring | Parameter | Details | |-----------|----------| | **Risperidone dosing** | Start 0.25–0.5 mg/day; titrate by 0.25–0.5 mg every 5–7 days; target 0.5–1.5 mg/day in divided doses | | **Maximum dose** | 6 mg/day (rarely needed) | | **Baseline labs** | Fasting glucose, lipid panel, prolactin, weight, BP, EPS assessment | | **Monitoring interval** | Every 3–6 months for metabolic parameters; weight/BP at each visit | | **Common side effects** | Weight gain (most significant), sedation, hyperprolactinemia, extrapyramidal symptoms (EPS), metabolic syndrome | | **Contraindications** | Seizure disorder (relative), cardiac arrhythmias, neuroleptic malignant syndrome history | ### Clinical Pearl: Why Risperidone Over Alternatives - **Aripiprazole** is also FDA-approved for ASD irritability but has weaker evidence for aggression specifically - **SSRIs** (fluoxetine, sertraline) are used for anxiety-driven behaviors, not primary aggression - **Stimulants** (methylphenidate) worsen aggression and self-injury in ASD - **Valproate** has no FDA approval for ASD and carries teratogenic and hepatotoxic risks ### Mnemonic: FDA-Approved Meds for ASD Irritability **"RARA"** = **Risperidone, Aripiprazole** (the two antipsychotics with FDA approval for ASD irritability) ### Warning: Common Pitfalls - ~~Using stimulants first~~ — they can exacerbate aggression and self-injury - ~~Starting SSRIs for primary aggression~~ — they are for anxiety-driven behaviors - ~~Omitting metabolic monitoring~~ — weight gain and metabolic syndrome are serious long-term risks - ~~Skipping behavioral interventions~~ — pharmacotherapy should complement, not replace, ABA and structured behavioral supports ### Stepped Care Algorithm 1. **Behavioral interventions** (ABA, visual schedules, sensory breaks, transition warnings) — 4–6 weeks trial 2. **If inadequate response:** Add pharmacotherapy - **Aggression/self-injury** → Risperidone or aripiprazole - **Anxiety-driven behaviors** → SSRI - **Hyperactivity** → Stimulant (only if no aggression) 3. **Baseline and periodic monitoring** of metabolic parameters, weight, prolactin [cite:DSM-5 Neurodevelopmental Disorders; Harrison 21e Ch 387; American Academy of Pediatrics Autism Toolkit]